780 BRANNAN STREET, SAN FRANCISCO, CA
Appoints Jason O’Byrne as Chief Financial Officer
Reports Second Quarter 2026 Financial and Operating Results
Annual Meeting Results; Election of Directors at Olema Pharmaceuticals
Announces Clinical Trial Collaboration and Supply Agreement to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
Reports First Quarter 2026 Financial and Operating Results
Material disclosure
Annual Report to Security Holders
Q2
Q1
FY 2025
Q3
FY 2024
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Additional Securities
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Additional Proxy Materials
Definitive Proxy Statement
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence